Erlocip contains erlotinib and belongs to a class of medications called kinase inhibitors.
Erlocip is used for the treatment of non-small cell lung cancer.
Erlocip is used in combination with gemcitabine for the treatment of pancreatic cancer that has spread to nearby tissues or to other parts of the body..
MECHANISM OF ACTION
Erlocip works by blocking the action of an abnormal protein that slows the growth of cancer c ells. This helps slow or stop the spread of cancer cells.
Erlocip is available as 150mg tablets.
Symptoms of overdose associated with Erlocip may include diarrhea and rash.
PRECAUTIONS & WARNINGS
The side effects associated with Erlocip are difficulty breathing, closing of the throat, swelling of the lips, tongue, face or hives, shortness of breath, increased coughing, fever, chest pain, severe or persistent nausea, vomiting, loss of appetite, diarrhea, eye pain or irritation, skin rash, dryness, itching, acne, weakness, blistering, peeling, dry, or cracked skin, itching, tenderness, burning of the skin, growth of eyelashes on the inside of the eyelid, unusual bruising or bleeding.
Erlocip is a prescription drug and should be used under proper medical guidance and advice. Do not share the medicine with others, since they may be suffering from a problem that is not effectively treated by this drug..